Company Monitoring Page for Biogen

latest headlines for company on cafepharma

Prothena rolls out preclinical data for anti-amyloid Alzheimer's candidate to rival Biogen's Aduhelm
Fierce Biotech
Mon, 07/26/21 - 10:09 pm
Tags:
Prothena, Alzheimer's disease, monoclonal antibodies, Biogen, Aduhelm, PRX012
Could These 3 Potential Blockbusters Transform Biogen?
Motley Fool
Mon, 07/26/21 - 09:04 am
Tags:
Biogen, zuranolone, depression, TMS-007, stroke, Aduhelm, Alzheimer's disease
Aduhelm has already generated $2M in revenue for Biogen
Beckers Hospital Review
Thu, 07/22/21 - 09:55 pm
Tags:
Biogen, earnings, Aduhelm, Alzheimer's disease
Biogen mounts defense of its Alzheimer’s drug, saying ‘misinformation’ is fueling controversy
Stat
Thu, 07/22/21 - 11:08 am
Tags:
Biogen, Aduhelm, Alzheimer's disease
Biogen’s Aduhelm: Slow to Launch with Controversy Continuing
BioSpace
Wed, 07/21/21 - 08:52 pm
Tags:
Biogen, Aduhelm, Alzheimer's disease, FDA, drug launches
Scandal aside, Biogen's Aduhelm sales set to reach $1B next year and $6B+ by 2025: analysts
Fierce Pharma
Tue, 07/20/21 - 12:37 pm
Tags:
Biogen, Aduhelm, Alzheimer's disease
Biogen, ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer's drug
Fierce Pharma
Fri, 07/16/21 - 10:35 am
Tags:
Biogen, Aduhelm, ICER
Major health centers, insurers push back against Aduhelm
BioPharma Dive
Thu, 07/15/21 - 11:16 pm
Tags:
Biogen, Aduhelm, insurers, Alzheimer's disease
Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas
Bloomberg
Thu, 07/15/21 - 10:45 am
Tags:
Biogen, Eisai, Alzheimer's disease, lecanemab, BAN2401
FDA chief Janet Woodcock acknowledges agency may have misstepped in process leading up to Alzheimer’s drug approval
Stat
Wed, 07/14/21 - 10:37 pm
Tags:
Janet Woodcock, FDA, Biogen, Aduhelm, Alzheimer's disease
Private insurers decline to cover Biogen's new Alzheimer's drug in escalating standoff — report
Endpoints
Wed, 07/14/21 - 10:50 am
Tags:
Biogen, Aduhelm, insurers, Alzheimer's disease
FDA staffers defend Aduhelm approval in JAMA editorial
Pharmaforum
Wed, 07/14/21 - 10:18 am
Tags:
FDA, Biogen, Aduhelm, JAMA, drug approvals, Alzheimer's disease
So far, so not-so-good: Neurologists slow to warm up to Biogen’s Alzheimer drug Aduhelm, study finds
Fierce Pharma
Tue, 07/13/21 - 11:43 pm
Tags:
Biogen, Aduhelm, neurologists, Alzheimer's disease
House committees kick off investigation into how Biogen's Aduhelm won approval
Endpoints
Tue, 07/13/21 - 10:48 am
Tags:
US Congress, Biogen, Aduhelm, FDA, drug approvals, Alzheimer's disease
Biogen builds MS pipeline via $125m deal with China’s InnoCare
Pharmaforum
Tue, 07/13/21 - 10:39 am
Tags:
Biogen, MS, multiple sclerosis, China, InnoCare
Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug
BioPharma Dive
Mon, 07/12/21 - 11:39 pm
Tags:
CMS, Medicare, Biogen, Aduhelm, Alzheimer's disease
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
Motley Fool
Sun, 07/11/21 - 11:13 pm
Tags:
clinical trials, Novartis, Biogen, SAGE Therapeutics, uniQure, Pfizer, Roche
FDA Head Calls for Inspector General Investigation of Aduhelm Approval
BioSpace
Sat, 07/10/21 - 12:01 am
Tags:
FDA, Janet Woodcock, Biogen, Aduhelm
FDA revises labeling of Biogen's Alzheimer's drug to emphasize early treatment
BioPharma Dive
Thu, 07/8/21 - 11:17 am
Tags:
Biogen, Aduhelm, FDA, Alzheimer's disease, labeling
Aduhelm’s accelerated approval offers a promising roadmap for rare neurological diseases
Stat
Wed, 07/7/21 - 10:36 pm
Tags:
FDA, Biogen, Aduhelm, accelerated approvals, neurodegenerative disease

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.